The stakeholders in healthcare in the developed world are conventionally divided into three ‘P’ words: patients, payers and pharmaceutical companies. In addition, there are a couple of other more minor players, namely physicians and pharmacists. Recent developments have, however, dramatically increased the importance and changed the role of one of these participants, the patient community.
Category Archives: Uncategorized
Because new medicines have such a high burden of R&D costs to recuperate, their commercialisation in a protected environment is essential to the innovator business model. That protection has historically been offered through the patent system, but for how much longer, given the increasing time taken to innovate?
There may be interesting cases…where the combination of a low-risk deuterated active can be combined with a new therapeutic use, and synergistically deliver a new product that is medically advantageous and significantly differentiated.